TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02254720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR solution for inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat®
Study: NCT03142672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: vital endodontic procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth filling
Description: tooth filling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth filling
Description: tooth filling
Study: NCT02633215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
Study: NCT02291913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Anti-estrogen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Anti-estrogen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Anti-estrogen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anti-estrogen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Anti-estrogen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifine
Description: Anti-estrogen therapy
Study: NCT02770326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Study: NCT03753932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed prosthodontics
Description: The intervention takes place six months after finishing radiotherapy.
Study: NCT02127749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Both groups will receive 2 ng/kg LPS (endotoxin) intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Both groups will receive 2 ng/kg LPS (endotoxin) intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin, Metronidazole, Ciprofloxacin
Description: ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
Study: NCT00926354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101
Description: intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
Study: NCT03621735

Intervention type: DEVICE
Group type: OTHER
Intervention: Burst-SCS/sham SCS
Description: The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks.
Study: NCT01287858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC430
Description: Healthy volunteers will either receive AC430 or placebo.
Study: NCT03494946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: May include chemotherapy, TACE, SIRT or other available treatment options.
Study: NCT01040494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
Study: NCT03621735

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham SCS/Burst-SCS
Description: Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks.
Study: NCT02993211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar transurethral standard resection
Description: Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral en bloc resection
Description: Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
Study: NCT04304937

Intervention type: OTHER
Intervention: patient reported outcome measure
Description: 2 questionnaires are tested against each other

Intervention type: OTHER
Intervention: patient reported outcome measure
Description: 2 questionnaires are tested against each other
Study: NCT03896087

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV assay from DBS
Description: The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
Study: NCT02340052

Intervention type: DRUG
Intervention: Pain treatment
Description: Registration af actual analgesic treatment and outcomes

Intervention type: DRUG
Intervention: Pain treatment
Description: Registration af actual analgesic treatment and outcomes

Intervention type: DRUG
Intervention: Pain treatment
Description: Registration af actual analgesic treatment and outcomes

Intervention type: DRUG
Intervention: Pain treatment
Description: Registration af actual analgesic treatment and outcomes

Intervention type: DRUG
Intervention: Pain treatment
Description: Registration af actual analgesic treatment and outcomes
Study: NCT01750489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation (NIV)
Study: NCT04719455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Improving self-Management Strategy
Description: An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Improving self-Management Strategy
Description: An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular care
Description: Treatment as usual (appointments with nurse/nurse practioner with regular content)

Intervention type: OTHER
Group type: OTHER
Intervention: Regular care
Description: Treatment as usual (appointments with nurse/nurse practioner with regular content)
Study: NCT03280849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant of bilaminar chitosan scaffold
Description: The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
Study: NCT04107740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-Trelin OD Tab(5mg Taltirelin Hydrate)
Description: BID, 10mg per day, for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, 10mg per day, for 24 weeks
Study: NCT01784211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study: NCT01607749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual Asthma Information for teachers
Description: Common asthma information for teachers
Study: NCT01486940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
Study: NCT01388491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desogestrel/ethinyl estradiol and ethinyl estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desogestrel/ethinyl estradiol
Study: NCT02761681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-CL Web-based guided self-help

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Web-based guided self-help
Study: NCT01596140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose 5.0 mg by mouth daily for 28-day study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
Study: NCT02624661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol
Study: NCT00806533

Intervention type: DRUG
Intervention: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)
Description: solution for intravenous infusion applied according to SmPC
Study: NCT04605458

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
Study: NCT00352170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium supplementation
Description: calcium carbonate 1500 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D3 supplementation
Description: calcium carbonate 1500 mg/day vitamin D3 1000 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: calcium and vitamin D3 placebo
Study: NCT01357720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quinvaxem
Description: A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quinvaxem/Tritanrix
Description: A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14
Study: NCT00523172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual or manipulative therapy
Description: Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual / Manipulative Therapy
Description: Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Supportive Care
Description: Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed.
Study: NCT01389076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexxar
Description: Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Methotrexate
Description: Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
Study: NCT04089228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Total of 4 sessions on upper trapezius trigger points on alternate days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Neuromuscular Inhibition Technique
Description: Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique
Description: Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
Study: NCT02992912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody atezolizumab
Description: 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody atezolizumab
Description: 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody atezolizumab
Description: 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 antibody atezolizumab
Description: 1200 mg every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SABR
Description: Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SABR
Description: Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SABR
Description: Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SABR
Description: Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
Study: NCT02845284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced group support
Description: Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced individual support
Description: Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
Study: NCT01636739

Intervention type: BIOLOGICAL
Intervention: Oral Rotarix®
Description: 2 doses administered orally.

Intervention type: OTHER
Intervention: Data collection
Description: Additional information on intussusception will be collected through interview and by phone-contact.
Study: NCT01609361

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation program
Description: Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
Study: NCT03600844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community distribution of SP for IPTp
Description: SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community distribution of SP for IPTp
Description: SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
Study: NCT00547729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartPOD™ System
Description: HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
Study: NCT02279134

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemoradiation
Description: Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Radiation
Description: Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-150mg/m2 (D1 and D29)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Nedaplatin
Description: 50-75mg/m2 (D1 and D29)
Study: NCT02456935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100 mg QD
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg QD
Description: Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.